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Aim. The purpose of this study was to evaluate the accuracy of 2-deoxy-2-[ﬂuorine-18]ﬂuoro-D-glucose (FDG) positron emission
tomography (PET), computed tomography (CT), and software-based image fusion of both modalities in the imaging of non-
Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD). Methods. 77 patients with NHL (n = 58) or HD (n = 19) underwent a
FDGPETscan,acontrast-enhancedCT,andasubsequentdigitalimagefusionduringinitialstagingorfollowup.109examinations
of each modality were evaluated and compared to each other. Conventional staging procedures, other imaging techniques,
laboratory screening, and follow-up data constituted the reference standard for comparison with image fusion. Sensitivity and
speciﬁcity were calculated for CT and PET separately. Results. Sensitivity and speciﬁcity for detecting malignant lymphoma were
90% and 76% for CT and 94% and 91% for PET, respectively. A lymph node region-based analysis (comprising 14 deﬁned
anatomicalregions)revealedasensitivityof81%andaspeciﬁcityof97%forCTand96%and99%forFDGPET,respectively.Only
three of 109 image fusion ﬁndings needed further evaluation (false positive). Conclusion. Digital fusion of PET and CT improves
the accuracy of staging, restaging, and therapy monitoring in patients with malignant lymphoma and may reduce the need for
invasive diagnostic procedures.
1.Introduction
The prognosis of Hodgkin’s disease (HD) and non-
Hodgkin’s lymphoma (NHL) has signiﬁcantly improved in
recent years. This is a result not only of new therapeutic
concepts,forexample,theimplementationofRituximab,but
also of accurate staging procedures and the early evaluation
of response during treatment. For staging and monitoring,
computed tomography (CT) is commonly used, but its
information is limited to anatomical criteria such as the size
of lymph nodes. Thus, for small lymph nodes malignancy
may be overlooked. Nevertheless, CT is still the most
commonly available technique for identiﬁcation of nodal
involvement,aswellasforstagingandrestagingofmalignant
lymphoma [1].
Positron emission tomography (PET) with 2-deoxy-
2-[ﬂuorine-18] ﬂuoro-D-glucose (FDG) is an established
imaging technique for malignant tumors [2–4] including
malignant lymphoma [5]. PET provides functional infor-
mation and allows metabolic measurements of malignant
lesions. FDG PET has been successfully used for evaluation
of tumor viability of a previously recognized active tumor
after therapy. It can diﬀerentiate between scar tissue or active
tumor tissue after treatment [6]. Many studies have shown
the beneﬁt of FDG PET in staging, restaging, and prediction
of response to treatment in malignant lymphoma [7, 8]. The
combinationofmetabolicandmorphologicalimaging,using
hybrid PET/CT scanners or software-based image fusion, is a
promising technique that might overcome the limitations of
each single modality [9–12]. By adding detailed anatomical2 The Scientiﬁc World Journal
information to the FDG PET, CT provides additional diag-
nostic information, thus enhancing the diagnostic accuracy
in patients with malignant lymphoma.
The purpose of this study was to evaluate the accuracy of
dedicated FDG PET, CT, and software-based image fusion.
Both imaging modalities were performed for NHL or Hodg-
kin’s disease. Results of this image fusion study may improve
the quality of image interpretation in institutions, where
both techniques are recorded at diﬀerent locations.
2.MaterialandMethods
2.1. Patients. Seventy-seven patients with lymphoma treated
at the Division of Haematology and Oncology, Medical
University Innsbruck, Austria, were examined.
All patients underwent CT and PET examination fol-
lowed by a software-based fusion of the two modalities.
Thirteen patients underwent two PET/CT investigations,
8 patients had three PET/CT follow-up controls, and 1
patient obtained four PET/CT reinvestigations. Altogether
109 examinations of each modality were available. Among
these, 14 scans were performed during initial staging, and
95 during restaging. Of the 77 included patients, 38 were
female and 39 were male (age range 20–77, mean 53). All
had histologically proven malignant lymphoma. Fifty-eight
Patients suﬀered from NHL and 19 from HD. Of the 58
patients with NHL, 25 had diﬀu s el a r g eBc e l ll y m p h o m a ,1 1
follicular lymphoma grade I-II, 6 follicular lymphoma grade
III, 6 mantle cell lymphoma, 4 marginal zone lymphoma,
3 Burkitt’s lymphoma, and 3 were unclassiﬁed according to
the WHO classiﬁcation [13, 14]( Table 1). Mean follow-up
timewas14months.Inaddition,allpatientsunderwentcon-
ventional staging procedures, such as clinical examination,
ultrasound, bone marrow biopsy, and laboratory screening.
2.2. CT Imaging Protocol. The CT examinations were
obtained using a Siemens multislice CT scanner (Somatom
Sensation Open, Erlangen, Germany). Patients were asked
to empty their bladder before the scan in order to reduce
imaging artifacts due to bladder ﬁlling. A bolus of Visipaque
320 (GE Healthcare, Chalfont St. Giles, UK), 2mL per kg
body weight, was injected intravenously. 3mm slices of
the neck, the thorax, and the abdomen were obtained in
expiration.
2.3. PET Imaging Protocol. PET scans were performed on a
GE Advance PET scanner (GE Medical Systems, Waukesha,
WI, USA). All patients were required to fast for at least
8h o u r sp r i o rt ot h eP E Ts c a ni no r d e rt oo p t i m i z et h e
tumor’s FDG uptake and to minimize the physiologic
uptake in musculature, myocardium, and fat tissue. For
this reason, a glucose level of 130mg/dL, or below was
mandatory. After intravenous injection of 370 MBq FDG,
patients were prohibited to move and speak in order
to minimize the physiologic muscle uptake. Though not
routinely administered, oral benzodiazepines were available
for nervous patients. Directly prior to imaging, patients were
also asked to empty their bladders. The patients were placed
Table 1: Histological NHL subtypes.
Pathological NHL subtypes Number of patients
Diﬀuse large B cell lymphoma 25
Follicular lymphoma grade I-II 11
Follicular lymphoma grade III 6
Mantle cell lymphoma 6
Marginal zone lymphoma 4
Burkitt lymphoma 3
Unclassiﬁed 3
in a comfortable supine position. The emission scan was
started 60 minutes after the injection of the radioisotope. For
attenuation correction, transmission scans were obtained by
using a germanium 68 external line source. A whole-body
acquisition was performed.
2.4. Reproducible Patient Fixation. A major problem in the
acquisition and fusion of two diﬀerent modalities is the
repeatability of the patient’s position between the two exam-
inations. An exactly corresponding anatomical situation is
required. Therefore, patients were positioned in a vacuum
mattress (Bluebag, Medical Intelligence, Schwabm¨ unchen,
Germany) by an experienced technical assistant. The air
is then withdrawn from the cushion, which turns the
ﬂexible cushion into a rigid ﬁxation device allowing for
exact repositioning of the patient. 4 external markers were
subsequently attached to the mattress, positioned in the
region of interest in every individual case. Image fusion was
doneseparatelybyusingexternalmarkersasreference,which
are ﬁxed to a vacuum mattress used to position the patient in
exactly the same position in both scans.
2.5. Software-Based Fusion. For the image fusion, CT and
PET studies were transferred to a Treon workstation
(Medtronic Inc., Louisville, CO, USA) via intranet. Image
registration can be done with external markers using
the Cranial 4 multimodality software. With the CT data
as a reference, 4 corresponding ﬁducials (markers) were
identiﬁed in the two diﬀerent datasets, and by using the
paired-point matching algorithm the two datasets were then
superimposed to each other.
2.6. Image Evaluation. An experienced nuclear medicine
physician interpreted the 18-FDG PET images and an
experienced radiologist read the CT images, blinded to the
other imaging modality. The CT criteria for malignancy
included the presence of organomegaly, an abnormal mass
or structural changes inside a normal-sized organ. Lymph
nodes were considered abnormal if the diameter was more
than the standard CT size criteria for individual lymph
node groups or because of abnormal contrast enhancement
and central necrosis [15–17]. For FDG-PET, the criteria
were the presence of abnormally increased tracer uptake
at each suspected site. No quantiﬁcation of FDG uptakeThe Scientiﬁc World Journal 3
Table 2: Results of patient-based analysis with CT.
TP TN FP FN N sens. spec. PPV NPV acc. χ   P(χ2) P(F)
Malignant lymphoma 45 45 14 5 109 90 76 76 90 82 45.2 <0.0001 <0.0001
Morbus Hodgkin 14 10 6 1 31 93 62 70 90 77 8.2 0.0041 0.0021
NHL 31 35 8 4 78 88 81 79 89 84 35.0 <0.0001 <0.0001
Low-grade NHL 9 7 5 1 22 90 58 64 87 72 3.6 0.057 0.031
High-grade NHL 22 25 2 1 50 95 92 91 96 94 35.3 <0.0001 <0.0001
TP: true positive, TN: true negative, FP: false positive, FN: false negative, N: number of subjects, sens.: sensitivity, spec.: speciﬁcity, PPV: positive predictive
value, NPV: negative predictive value, acc.: accuracy, P(χ2): P value for Pearson’s Chi-squared test with Yates’ continuity correction, and P(F): P value for
Fisher’s Exact Test for Count Data.
Table 3: Results of lymph node region-based analysis with CT.
TP TN FP FN N sens. spec. PPV NPV acc. χ   P(χ2) P(F)
Malignant lymphoma 133 1334 29 30 1526 81 97 82 97 96 961 <0.0001 <0.0001
Morbus Hodgkin 53 353 14 14 434 79 96 79 96 93 240 <0.0001 <0.0001
NHL 80 981 15 16 1092 83 98 84 98 97 728 <0.0001 <0.0001
Low-grade NHL 20 278 5 5 308 80 98 80 98 96 178 <0.0001 <0.0001
High-grade NHL 60 624 7 9 700 86 98 89 98 97 520 <0.0001 <0.0001
Column headings as in Table 2,w i t hN: number of regions.
of the lesions was done. All suspected ﬁndings at PET or
at CT were documented. Afterwards, the ﬁndings of each
method were discussed in an interdisciplinary image fusion
conference. Finally, not only lymphoma lesions but also
additional diagnostic ﬁndings from both modalities, like
hernia, diverticulosis, or cholelithiasis, were documented.
To structure analysis of CT and PET images, the
body was divided into 14 anatomic lymph node regions
(cervical, nuchal, supraclavicular, infraclavicular, Waldeyer’s
ring, submandibular, axillary, hilar, mediastinal, pulmonary,
upper abdominal, lower abdominal, iliac, and inguinal) and
for each region, disease was recorded as present or absent.
Thus, in total the large number of 1526, single regions were
reviewed.
2.7. Reference Standards and Data Analysis. For the evalu-
ation of tumor imaging methods, a major problem is the
deﬁnition of the “gold standard” against which the diﬀerent
modalities should be compared. A histological conﬁrmation
of all sites suspicious of lymphoma involvement is virtually
impossible. We deﬁned the standard of reference as the sum
of many factors including the clinical follow-up data (mean
14 months) such as physical examination or ultrasound,
bone marrow and lymph node biopsy, and laboratory
screening. Thus, the ﬁndings of each modality (PET, CT
and software-based image fusion) were classiﬁed as true
positive, true negative, false positive, or false negative. For
the evaluation of the single CT and PET examination the
results of the image fusion were also included to the “gold-
standard.”
Inordertoanalysethisstudymoreprecisely,weevaluated
the results on a per patient analysis and on a lymph node
basis. In the per patient analysis, any suspected lymph node
in any of the deﬁned regions leads to a positive result. If
CT or PET ﬁndings were concordant to the “gold standard,”
they were regarded as truly positive or truly negative. This is
especially important due to the fact that most of the scans
were performed during restaging (87%).
The lymph node region-based analysis should show
w h e t h e ral y m p hn o d er e g i o ni sa ﬀected or not.
Finally, results of the fusion were compared with the
clinical stage after complete followup. The patients were
divided into subgroups (Hodgkin’s disease, non-Hodgkin
lymphoma, high-, and low-grade NHL).
2.8. Statistics. Statistical analysis was done utilizing the R
system for statistical computation. Pearson’s Chi-squared
test with Yates’ continuity correction and Fisher’s exact test
for count data were performed on all contingency tables
by means of batch processing [18]. Sensitivity, speciﬁcity,
positive predictive value, negative predictive value, and
accuracy were calculated by standard methods.
Statistical analysis was performed using the Statistical
Package for the Social Sciences for Windows (Release 13;
SPSS Inc., Chicago, IL, USA).
3. Results
3.1. CT. In total, 162/1526 suspicious lymph node regions
were detected by CT. The patient-based analysis (Table 2)
showed an overall sensitivity and speciﬁcity of 90% and 76%
according to 45 true positive and 45 true negative patients.
The CT resulted in 5 false-negative and 14 false-positive
patients. In patients with Hodgkin’s disease a sensitivity of
93% and speciﬁcity of 62% were calculated, for patients
with NHL 88% and 81%, respectively. For low-grade B-cell4 The Scientiﬁc World Journal
Table 4: Results of patient-based analysis with PET.
TP TN FP FN N sens. spec. PPV NPV acc. χ   P(χ2) P(F)
Malignant Lymphoma 48 53 5 3 109 94 91 90 94 92 76.0 <0.0001 <0.0001
Morbus Hodgkin 14 14 2 1 31 93 87 87 93 90 17.2 <0.0001 <0.0001
NHL 34 39 3 2 78 94 92 91 95 93 55.8 <0.0001 <0.0001
Low-grade NHL 13 7 2 0 22 100 77 86 100 90 11.5 0.0007 0.0002
High-grade NHL 21 26 1 2 50 91 96 95 92 94 35.2 <0.0001 <0.0001
Column headings as in Table 2.
Table 5: Results of lymph node region-based analysis with PET.
TP TN FP FN N sens. spec. PPV NPV acc. χ   P(χ2) P(F)
Malignant lymphoma 159 1348 13 6 1526 96 99 92 99 98 1330 <0.0001 <0.0001
Morbus Hodgkin 66 361 6 1 434 98 98 91 99 98 377 <0.0001 <0.0001
NHL 93 987 7 5 1092 94 99 93 99 98 940 <0.0001 <0.0001
Low-grade NHL 23 280 3 2 308 92 98 88 99 98 234 <0.0001 <0.0001
High-grade NHL 66 627 4 3 700 95 99 94 99 99 613 <0.0001 <0.0001
Column headings as in Table 2,w i t hN: number of regions.
lymphoma, the sensitivity and speciﬁcity were 90% and 58%
and for high-grade B-NHL 95% and 92%.
The lymph node region-based analysis revealed a sen-
sitivity of 81% for detecting 133 true positive regions, 30
regions were false negative and 29 false positive (Table 3). By
contrast, CT revealed also additional ﬁndings, for example,
diverticulosis (n = 2), nephrolithiasis (n = 1), cholelithiasis
(n = 2),aorticaneurysm(n = 1),abdominal-hernia(n = 3),
ap a n c r e a t i cc y s t( n = 1), and a pericardial eﬀusion (n = 1);
which were not detected by FDG-PET.
3.2. PET. In total, FDG PET detected 172/1526 suspicious
lymph node regions and showed a sensitivity of 94% and a
speciﬁcity of 91% in the per patients analysis (Table 4). In 48
patients, the PET scan was true positive and in 53 patients
true negative. 3 false-negative and 5 false-positive scans were
noted. In the analysis of patients with Hodgkin’s disease, the
sensitivity and speciﬁcity were 93% and 87%. For all NHL
subtypes it was 94% and 92%, respectively. In low-grade
lymphomas, the sensitivity and speciﬁcity were 100% and
77%, in patients with high-grade lymphoma 91% and 96%.
Using the lymph node region-based evaluation, sensitiv-
ity of FDG-PET was 96% for all lymphomas (Table 5). With
PET, 159 regions were true positive, 13 false positive, and
only 6 false negative.
3.3. Image Fusion. Comparing the image fusion to the
follow-up of the patients, 3 were found to be false positive
and 106/109 were true positive which results in a sensitivity
of 97%. In two patients, an axillary lymph node, which was
suspected to be malignant in the image fusion, was identiﬁed
as inﬂammatory by needle biopsy and histologic evaluation.
A hypermetabolic mediastinal mass in one patient was not
further investigated.
4. Discussion
To our knowledge, this is one of the largest cohort of patients
with malignant lymphoma in which PET and CT scans are
compared with each other.
The aim of this study was to evaluate if digitally fused
CT and PET images can improve the diagnostic accuracy
for the staging and monitoring of patients with malignant
lymphoma. A substantially better result could be achieved
by image fusion compared to CT or PET alone. In our
study, image fusion was equivocal (false positive) in 3
cases out of 109 (2.8%), which is obviously more accurate
than CT and PET alone. Thus, software-based fusion is
an interesting alternative for hospitals that do not have
access to an integrated PET/CT scanner. In addition, a
retrospective image fusion of PET and CT, or even MRI
images, allows most accurate image interpretation adopted
to the individual patient. We used a paired-point matching
algorithm to superimpose both datasets to each other, which
diﬀers from the automated rigid registration for image
fusion as described earlier in the literature by Wolz et al.
[19] and Slomka et al. [20]. To our experience in routine
external ﬁducials are easier to detect in both datasets and
allow for faster gained image fusion on navigation systems.
Thus, image fusion using external ﬁducial markers is a
simple and practical method which allows for routine use
in clinical settings. The accuracy of image fusion depends
largely on exact and stable positioning of the patient during
scans, movement of internal organs, artefacts caused by
PET attenuation correction, and misregistration of the two
modalities.
Nevertheless, a limitation of our study is that no
deﬁnition for a cut-oﬀ level for a “successful fusion” has
been stated, and to date, no literature about the accuracy and




Figure 1: First row: computed tomography image; second row: software-based image fusion; third row: F18-FDG PET. Axial, coronal, and
sagittal reformatted images of a patient with malignant lymphoma. F18-FDG PET (third row) shows a false-positive abdominal lesion (it
was also scored as false positive) which turned out to be related to ureter-activity as showing by image fusion of PET with CT (second row).
CT images did not show any pathologic enlarged lymph node. (ﬁrst row).
Raanani et al. showed that additional diagnostic CT may
be obviated in the PET/CT era, but not for all patients [21].
Osman et al. found a beneﬁt for 3% of all cases when using
a diagnostic scan—important ﬁndings may be overlooked
without CT [22]. In our study, we found many important
additional ﬁndings with CT, for example, diverticulosis,
aortic aneurysm and nephrolithiasis; most of which cannot
be seen with PET. Diagnostic CT is still an important tool
and should not be relegated to being only a simple map for
PET. The additional ﬁndings diagnosed by CT support the
use of at least an initial diagnostic CT scan with intravenous
contrast for the protocol of integrated PET/CT [23, 24].
In many studies, the advantage of PET in lymphoma [25]
anditsroutineusagewassuggestedinthestagingandfollow-
up of lymphoma patients [26, 27]. With FDG-PET our study




Figure 2: Axial, coronal, and sagittal reformatted images of a patient showing a typical “pitfall” with F18-FDG PET (third row). A
positive bilateral cervical activity could be identiﬁed as activated brown fat tissue by using image fusion (second row). ﬁrst row: computed
tomography image; second row: software-based image fusion; third row: F18-FDG PET.
for all types of malignant lymphoma. These results are in
concordance with the literature. Bangerter et al. showed a
sensitivity of 96% and a speciﬁcity of 94% with PET in
lymphoma of the thorax in 89 consecutive patients [8].
However, FDG is not a tumor-speciﬁc tracer. An increased
glucose metabolism may also relate to other pathologic as
well as physiologic conditions. In most of our cases it was
possible to exclude false positive ﬁndings by the combination
of CT and PET (Figure 1).
Surprisingly, the sensitivity and speciﬁcity for NHL were
higher (94% and 92%) than in Hodgkin’s disease, with 93%
and 87%, respectively. An issue that is still under debate
is the beneﬁt of FDG PET in the staging and followup of
low-grade lymphoma and among the diﬀerent histologic
subtypes.Somestudiesreportedahighersensitivityforhigh-
grade than low-grade lymphoma [28–33]. Our study showed
no signiﬁcant diﬀerence between both, more precisely not
signiﬁcantly more false-negative and false-positive resultsThe Scientiﬁc World Journal 7
in low-grade than in high-grade lymphoma—both could
be detected by FDG PET. Our results are in concordance
with studies that could also show no signiﬁcant problems
in detecting low-grade lymphoma [34–36]. However, the
speciﬁcity in low-grade lymphoma in the patient-based
statistic was only 77% compared to 96% in high-grade
lymphoma. CT reached 92% sensitivity and only 44%
speciﬁcity in low-grade lymphoma which is less accurate
than PET. The study of Najjar et al. showed a sensitivity of
87% and a speciﬁcity of 87% with FDG PET in 36 patients
with histological proven low-grade NHL, and CT had 90%
and 100%, respectively [37].
In the lymph node region-based analysis, PET was true
positive in 159 out of 165 lesions showing the high accuracy
of FDG PET in detecting aﬀected lymph nodes.
The low anatomical resolution of PET and the variability
in normal physiologic FDG uptake in the body can be
challenging, especially in the abdomen and pelvis [38]o r
cervicalregions.However,suchdiﬃcultanatomicallocations
and imaging pitfalls [39] can be circumvented by fusing CT
and PET images (Figure 2). Similar to the data of La Foug` ere
et al., an advantage of PET over CT alone was observed. Still,
they could not show any signiﬁcant diﬀerence between fused




The lymph node region-based analysis gives precise
information about the accuracy in detecting aﬀected lymph
nodes by the methods applied. The results of this analysis
show how many of the 14 deﬁned regions were truly aﬀected.
Due to the high number of true negative regions, the
speciﬁcity of all the region-based analysis is not signiﬁcant
(Tables 3 and 5).
Freudenberg et al. had a sensitivity of 78% for CT and
86% for PET in restaging of 27 patients with lymphoma
[42]. Weihrauch et al. showed a sensitivity of 74% and
88% for CT and PET but a speciﬁcity of 100% for both
imaging modalities in staging Hodgkin’s disease [43]. Our
data, relating to sensitivity, are also compatible with the data
of Stumpe et al., but their speciﬁcity of CT is only between
41% and 67% [44]. Schaefer et al. reported a sensitivity
of 50% for contrast enhanced CT in detecting organic
involvement with lymphoma. For statistical interpretation
they deﬁned only 6 lymph node regions and 5 organs for
estimatingorganicinvolvement;inlymphnodeinvolvement,
CT showed 88% sensitivity. They compared it to integrated
PET/CT which showed 88% for organ involvement and 94%
for lymph node involvement. They included 60 patients in
their study [45]. Tatsumi et al. also used a combined PET/CT
scanner to analyse lesions at the same anatomic locations in
53 patients with lymphoma. Their purpose was to compare
FDG PET and CT in order to evaluate the frequency and
causes of discrepant ﬁndings between both modalities. Of
the 1537 determined anatomic sites, 48 showed discordant
ﬁndings; 40 (83%) of these had correct PET ﬁndings, and
only 5 had correct CT ﬁndings, 3 remained unresolved.
However, in contrast to our study no intravenous contrast
material was applied for the CT acquisition [46]. Our results
with software-based image fusion in patients with malignant
lymphoma correspond to results in surveys with integrated
PET-CT scanners.
A limitation inherent to CT is that normal size or
borderline lymph nodes harbouring a malignant and active
disease may be diagnosed as normal because no pathologic
criteria as size, shape or contrast enhancement can be
identiﬁed. There is also a problem in diﬀerentiation between
malignant and inﬂammatory enlargement of lymph nodes.
However, our study with CT showed an excellent sensitivity
of 90% in detecting a malignant process (per patient) and
81% for detecting malignant lymph node regions. One
reason for the better results compared to other studies might
be the technical beneﬁt of the multislice CT scanner and the
application of contrast media. The 14 false-positive patients
were due to enlarged lymph nodes that had not yet shrunk
after the therapy or because of benign “reactive” lymph
nodes.Thisisexplainedbythefactthatthedecreaseoflymph
node size does not follow a decrease of the metabolic activity.
Remarkably, the speciﬁcity of CT in Hodgkin’s disease
and low-grade NHL were only 62% and 44% in the patient-
based evaluation—we could ﬁnd no possible explanation for
that.
The poorest sensitivity for CT (79%) in our study was
achieved in HD with a total of 14 false-positive and 14 false-
negative lymph node regions.
FDG PET was responsible for 13 false-positive lymph
node regions which caused 5 false-positive patients. Without
combiningPETwithananatomicalmethod,thiscouldresult
in crucial wrong decisions in treatment management.
5. Conclusion
The aim of this study was to evaluate the clinical signiﬁcance
of CT and PET alone compared to a combination by using
software-basedfusion.Imagefusionisahelpfultechniquefor
both staging and followup in patients with malignant lym-
phoma. Diﬀerences between PET and CT sensitivities were
not signiﬁcant but the combination of both technologies is
considerably more accurate than each modality on its own,
posing an interesting alternative for hospitals that do not
have access to an integrated PET/CT scanner.
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